Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07300839 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 13, 2026 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 25500 to confirmed 5240 · Study sites: 208 to 196v2 Show 2 more changesShow less
    • Enrollment target: estimated 25500 to confirmed 5240
    • Study sites: 208 to 196
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
BioNTech SE
49 trials monitored
See 3 trials at risk
This study is designed to find out how well the COVID-19 vaccine protects people 50 to 64, who don't have any serious health problems, compared to a group that receives a vaccine that doesn't contain an ingredient to protect against COVID-19 (placebo).
Trial Details
NCT Number NCT07300839
Lead Sponsor BioNTech SE
Collaborators: Pfizer
Conditions COVID-19, SARS-COV-2 Infection
Enrollment 5,240 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov